Please login to the form below

Not currently logged in
Email:
Password:

Genzyme’s Richard Moscicki joins FDA

Provides regulatory agency with more than 20 years of industry experience

FDA, Richard MoscickiThe US Food and Drug Administration (FDA) has appointed Genzyme's Dr Richard Moscicki to the newly created position of deputy centre director for science operations at its Center for Drug Evaluation and Research (CDER).

Dr Moscicki, who currently serves as senior VP, head of clinical development at Sanofi's Genzyme division, will help lead the CDER in its role to regulate over-the-counter and prescription-only drugs available in the US.

The FDA will benefit from his strong industry background in research, which includes time spent as medical director and chief medical officer at Genzyme.

He also gained regulatory and pharmacovigilance experience at the US-based biotech, serving as its senior VP of biomedical and regulatory affairs from 1996 to 2011.

In his role at the FDA, Dr Moscicki will work with Dr Bob Temple, deputy director for clinical science, and Dr Doug Throckmorton, deputy director for regulatory programmes.

14th February 2013

From: Research, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics